Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases.
Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, whom received apatinib (250mg or 500mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second- or more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS) and safety were analyzed. A total of 26 eligible patients were included: 24 patients diagnosed with adenocarcinoma, 2 with squamous carcinoma, and 14 patients harboring EGFR sensitizing mutations. The mPFS and mOS were 4.93 (range, 0.27-32.91; 95%CI 3.64-6.22) and 14.70 (range, 0.27-32.91; 95%CI 0.27-43.60) months for the whole group. The ORR and DCR were 7.7% (2/26) and 69.2% (18/26) for the entire lesions, and 7.7% (2/26) and 79.6% (20/26) for brain metastases, respectively. Compared with patients who received apatinib monotherapy, patients who received apatinib combination treatment had more favorable mPFS (11.77 vs. 2.27 months, P < 0.05) and mOS (24.03 vs. 6.07 months, P < 0.05). Treatment-related toxicities were tolerable including grade 1/2 hypertension, hand and foot syndrome, fatigue, nausea, liver dysfunction, myelosuppression, skin rash and palpitation. In conclusion, apatinib exhibited highly activity and good tolerance for NSCLC patients with brain metastasis and it might become a potential choice for metastatic brain tumors in NSCLC patients.